Datasheet: MCA752S

Description:	MOUSE ANTI GUINEA PIG CD8
Specificity:	CD8
Format:	Con S/N
Product Type:	Monoclonal Antibody
Clone:	CT6
Isotype:	IgG1
Quantity:	0.25 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/100
Immunohistology - Frozen	▪			1/100
Immunohistology - Paraffin			▪	
ELISA			▪	
Immunoprecipitation			▪	
Western Blotting			▪	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Guinea Pig
Product Form	Concentrated tissue culture supernatant - liquid
Preservative Stabilisers	0.1% Sodium Azide 0.7% Bovine Serum Albumin
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Guinea pig peritoneal T-cells.
RRID	AB_324551

Fusion Partners	Spleen cells from immunized BALB/c mice were fused with cells of the X63.Ag8.653 mouse myeloma cell line.
Specificity	**Mouse anti Guinea Pig CD8 antibody, clone CT6** reacts with guinea pig CD8 present on cytotoxic T-cells. CD8 comprises 2 subunits, alpha and beta and exists as either an alpha/alpha homodimer or an alpha/beta heterodimer. Sequence analysis suggests that guinea pig CD8 is more closely related to human than rat or mouse CD8 (Nagarajan *et al.* 2004).
Flow Cytometry	Use 10ul of the suggested working dilution to label 10^6 lymphocytes in 100ul.

References

1. Tan, B.T.G. *et al.* (1985) Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. Hybridoma 4: 115-124.
2. Steerenberg, P.A. *et al.* (1991) Tumour rejection after transfer of line 10 immunity is mediated by two T-cell populations. Cancer Immunol. Immunother. 34: 103-110.
3. Steerenberg, P.A. *et al.* (1990) Tumour infiltrating leucocytes (tils) during progressive tumour growth and BCG - mediated tumour regression. Virchows Archiv Cell Pathol. 59: 185-194.
4. Baker, D. *et al.* (1987) Changes in lymphocyte subsets after treatment with cyclophosphamide and during the development of contact sensitivity in the guinea pig. Int J Immunopharmacol. 9 (2): 175-83.
5. Antoniou, A.V. *et al.* (1986) Immunocytochemical identification and quantitation of mononuclear cells in the meninges during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig. Cell Immunol. 97 (2): 386-96.
6. Liversidge, J. *et al.* (1987) EAU in the guinea pig: inhibition of cell-mediated immunity and Ia antigen expression by cyclosporin A. Clin Exp Immunol. 69 (3): 591-600.
7. Liversidge, J. & Forrester, J.V. (1988) Experimental autoimmune uveitis (EAU): immunophenotypic analysis of inflammatory cells in chorio retinal lesions. Curr Eye Res. 7 (12): 1231-41.
8. Debout, C. *et al.* (1991) The Kurloff cell in estrogenized guinea pigs as a CT7+ 8BE6- CT6- MR-1- CT10- IgM- lymphocyte with natural killer activity. Nat Immun Cell Growth Regul. 10 (6): 327-35.
9. Shang S *et al.* (2011) Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother. 55 (1): 124-31.
10. Lacy HM *et al.* (2011) Essential role for neutrophils in pathogenesis and adaptive immunity in *Chlamydia caviae* ocular infections. Infect Immun. 79 (5): 1889-97.
11. Komori, T. *et al.* (2011) A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity. J Biol Chem. 286: 16800-6.
12. Hiromatsu, K. *et al.* (2002) Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. J Immunol. 169: 330-9.
13. Kramp, J.C. *et al.* (2011) The *in vivo* immunomodulatory effect of recombinant tumour necrosis factor-alpha in guinea pigs vaccinated with *Mycobacterium bovis* bacille Calmette-Guérin. Clin Exp Immunol. 165: 110-20.
14. Mishra, N.C. *et al.* (2010) Sulfur mustard induces immune sensitization in hairless guinea pigs. Int Immunopharmacol. 10: 193-9.

15. Schleiss, M.R. *et al.* (2007) Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis. 195: 789-98.
16. Turner, O.C. *et al.* (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with *Mycobacterium tuberculosis*. Infect Immun. 71: 864-71.
17. Wang, Y. *et al.* (2010) Local host response to chlamydial urethral infection in male guinea pigs. Infect Immun. 78: 1670-81.
18. Yang, H. *et al.* (2011) Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of *Mycobacterium tuberculosis* infection. Infect Immun. 79: 716-23.
19. Baldwin SL *et al.* (2012) The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol. 188 (5): 2189-97.
20. Obregón-Henao, A. Shang, s. Shanley, C.A. Basaraba, R.J. Caraway, M.L. Duncan, C.G. Ordway, D.J. Orme, I.M. (2013) Cortisone-Forced Reactivation of Weakly Acid Fast Positive Mycobacterium Tuberculosis in Guinea Pigs Previously Treated With Chemotherapy Mycobacterial Diseases. 2: 116.
21. Xia, J. *et al.* (2014) Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs. PLoS One. 9 (12): e114652.
22. Jeevan A *et al.* (2013) Guinea pig skin, a model for epidermal cellular and molecular changes induced by UVR in vivo and in vitro: effects on *Mycobacterium bovis* Bacillus Calmette-Guérin vaccination. Photochem Photobiol. 89 (1): 189-98.
23. Gupta A *et al.* (2012) Protective efficacy of *Mycobacterium indicus pranii* against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine. 30 (43): 6198-209.
24. Gupta, A. *et al.* (2012) Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 7 (7): e39215.
25. Wu, W.H. *et al.* (2012) Immune status and the development of *Listeria monocytogenes* infection in aged and young guinea pigs. Clin Invest Med. 35 (5): E309.
26. Eckhardt, E. *et al.* (2023) Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from *Mycobacterium tuberculosis* challenge. Sci Rep. 13 (1): 18613.

Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #10495 available at: https://www.bio-rad-antibodies.com/SDS/MCA752S 10495
Regulatory	For research purposes only

Related Products

Recommended Secondary Antibodies

Rabbit Anti Mouse IgG (STAR12...)	RPE
Goat Anti Mouse IgG IgA IgM (STAR87...)	HRP
Goat Anti Mouse IgG (STAR76...)	RPE
Rabbit Anti Mouse IgG (STAR13...)	HRP
Goat Anti Mouse IgG (STAR70...)	FITC
Goat Anti Mouse IgG (H/L) (STAR117...)	Alk. Phos., DyLight®488, DyLight®550, DyLight®650, DyLight®680, DyLight®800, FITC, HRP
Rabbit Anti Mouse IgG (STAR9...)	FITC
Goat Anti Mouse IgG (STAR77...)	HRP
Goat Anti Mouse IgG (Fc) (STAR120...)	FITC, HRP

North & South America Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com

Europe Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M418640:230427'

Printed on 19 Jan 2024